Patients (n = 120)
Characteristic . | Value . |
|---|---|
| Median patient age, y (range) | 54 (6-73) |
| Recipient sex, no. M/no. F (%) | 80 (67)/40 (33) |
| Median donor age, y (range) | 47 (19-78) |
| Donor sex, no. M/no. F (%) | 70 (58)/50 (42) |
| Female donor/male recipient, no. patients (%) | 35 (29) |
| Diagnosis, no. patients (%) | |
| Acute myeloid leukemia | 14 (12) |
| Acute lymphoblastic leukemia | 2 (2) |
| Chronic myeloid leukemia | 14 (12) |
| Chronic lymphocytic leukemia | 13 (11) |
| Myelodysplastic syndrome | 20 (17) |
| Multiple myeloma | 24 (20) |
| Non-Hodgkin lymphoma | 19 (16) |
| Hodgkin disease | 11 (9) |
| Waldenström macroglobulinemia | 3 (2) |
| Indolent* | 61 (51) |
| Aggressive† | 59 (49) |
| Intensity of pretransplantation chemotherapy,‡no. patients (%) | |
| Grade 0 | 17 (14) |
| Grade 1 | 103 (86) |
| Previous autograft, no. patients (%) | 42 (35) |
| CMV risk group, no. patients (%) | |
| Low (R-, D-) | 26 (22) |
| Intermediate (R-, D+) | 20 (17) |
| High (R+) | 74 (62) |
| Donor, no. patients (%) | |
| HLA-identical related donor | 85 (71) |
| HLA-Matched unrelated donor | 35 (29) |
| Hematopoietic stem cell source, no. patients (%) | |
| G-PBMC | 110 (92) |
| Bone marrow | 10 (8) |
| Conditioning regimen, no. patients (%) | |
| 2 Gy TBI | 45 (38) |
| 2 Gy TBI + fludarabine | 75 (62) |
| Cell dose, median (range) | |
| CD34+ cells, × 106/kg recipient | 7.2 (0.9-42.6) |
| T cells, × 106/kg recipient | 338 (16-760) |
| Monocytes, × 106/kg recipient | 292 (2-719) |
| Sustained engraftment/graft rejection, no. patients (%) | 108 (90)/12 (10) |
| Acute GVHD, no. patients (%) | |
| Grade 0 | 45 (37) |
| 1 | 8 (7) |
| 2 | 49 (41) |
| 3 | 11 (9) |
| 4 | 7 (6) |
| Chronic GVHD, no. patients (%) | |
| No | 78 (65) |
| Yes | 42 (35) |
| One-year overall survival, % | 63 |
| One-year progression-free survival, % | 50 |
| Measurable disease at HCT, no. patients (%) | 93 (78) |
Characteristic . | Value . |
|---|---|
| Median patient age, y (range) | 54 (6-73) |
| Recipient sex, no. M/no. F (%) | 80 (67)/40 (33) |
| Median donor age, y (range) | 47 (19-78) |
| Donor sex, no. M/no. F (%) | 70 (58)/50 (42) |
| Female donor/male recipient, no. patients (%) | 35 (29) |
| Diagnosis, no. patients (%) | |
| Acute myeloid leukemia | 14 (12) |
| Acute lymphoblastic leukemia | 2 (2) |
| Chronic myeloid leukemia | 14 (12) |
| Chronic lymphocytic leukemia | 13 (11) |
| Myelodysplastic syndrome | 20 (17) |
| Multiple myeloma | 24 (20) |
| Non-Hodgkin lymphoma | 19 (16) |
| Hodgkin disease | 11 (9) |
| Waldenström macroglobulinemia | 3 (2) |
| Indolent* | 61 (51) |
| Aggressive† | 59 (49) |
| Intensity of pretransplantation chemotherapy,‡no. patients (%) | |
| Grade 0 | 17 (14) |
| Grade 1 | 103 (86) |
| Previous autograft, no. patients (%) | 42 (35) |
| CMV risk group, no. patients (%) | |
| Low (R-, D-) | 26 (22) |
| Intermediate (R-, D+) | 20 (17) |
| High (R+) | 74 (62) |
| Donor, no. patients (%) | |
| HLA-identical related donor | 85 (71) |
| HLA-Matched unrelated donor | 35 (29) |
| Hematopoietic stem cell source, no. patients (%) | |
| G-PBMC | 110 (92) |
| Bone marrow | 10 (8) |
| Conditioning regimen, no. patients (%) | |
| 2 Gy TBI | 45 (38) |
| 2 Gy TBI + fludarabine | 75 (62) |
| Cell dose, median (range) | |
| CD34+ cells, × 106/kg recipient | 7.2 (0.9-42.6) |
| T cells, × 106/kg recipient | 338 (16-760) |
| Monocytes, × 106/kg recipient | 292 (2-719) |
| Sustained engraftment/graft rejection, no. patients (%) | 108 (90)/12 (10) |
| Acute GVHD, no. patients (%) | |
| Grade 0 | 45 (37) |
| 1 | 8 (7) |
| 2 | 49 (41) |
| 3 | 11 (9) |
| 4 | 7 (6) |
| Chronic GVHD, no. patients (%) | |
| No | 78 (65) |
| Yes | 42 (35) |
| One-year overall survival, % | 63 |
| One-year progression-free survival, % | 50 |
| Measurable disease at HCT, no. patients (%) | 93 (78) |
Defined as acute myeloid leukemia in first complete remission, acute lymphoblastic leukemia in first complete remission, myelodysplastic syndrome-refractory anemia, chronic myeloid leukemia in first chronic phase, chronic lymphoblastic leukemia, low-grade non-Hodgkin lymphoma, multiple myeloma in partial or complete remission, and Waldenström macroglobulinemia.
All other diagnoses.
Patients who did not receive chemotherapy or received agents such as chlorambucil, hydroxyurea, imatinib mesylate, or immunomodulators were graded as 0. Patients who received more intensive chemotherapy were graded as 1.
M indicates male; F, female; R, recipient; D, donor; G-PBMC, G-CSF-mobilized peripheral blood mononuclear cells; TBI, total body irradiation; and GVHD, graft-versus-host disease.